Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy

1 Dec 2022

Abstract excerpt

Although multiple studies have shown that loss of heterozygosity (LOH) at the human leukocyte antigen (HLA) locus is one of the mechanisms of immune escape, the effect of HLA LOH on the immunotherapy response of patients is still unclear. Based on the data of 425 Chinese lung cancer patients, the genomic characteristics with different HLA LOH statuses were analyzed. The driver genes mutation frequency, oncogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Ferroptosis and cancer prognosis
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36531232
DOI: 10.3389/fgene.2022.1066636

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapyPMID 36531232Read ↗

The prevalence of HLA-I LOH in Chinese pan-cancer patients and genomic features of patients harboring HLA-I LOHSemantic proximity Read ↗

Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.Semantic proximity Read ↗

Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancerSemantic proximity Read ↗

Frequency changes in HLA-I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD-L1 expression.Semantic proximity Read ↗

Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapySemantic proximity Read ↗

Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.Semantic proximity Read ↗

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patientsSemantic proximity Read ↗

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

Assessment of Immune Status of Laryngeal Squamous Cell Carcinoma Can Predict Prognosis and Guide TreatmentSemantic proximity Read ↗

MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution.Semantic proximity Read ↗

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.Semantic proximity Read ↗

Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.